Hutchmed (china) Share Discussion Threads

[steeplejack] 26/2/2021 20:25

Completely agree.Maybe the Chinese authorities don't want HCM to "endorse" Hong Kong by filing for a listing there.I suppose we'll just have to put it down to the Alibaba effect.Anyway,i sold a few at 5 quid some weeks back because there's inevitability about the inertia here compounded by the AIM market treating the stock with something approaching contempt.The company seems incapable of meaningful promoting its own cause.Maybe this doesn't merit being treated as a core holding and reluctantly i think i'll sell more on any meaningful price recovery.Oh ,i'll keep a reasonable slug so i can hopefully admonish myself for impatience but one feels you could go away for months and revisit this stock and find it languishing.

[nerdofsteel] 25/2/2021 09:13

that's true Rabid, although NASDAQ control the price here now, thanks to tiny volumes traded in London

[rabiddog] 24/2/2021 16:02

Hcm was on the IG margin list hxxps://www.ig.com/content/dam/publicsites/igcom/uk/210219_IGM_UK_Affected%20Markets%20-%20Non%20TT.pdf probably explains sell off this week

[steeplejack] 24/2/2021 08:22

Market makers treat this stock like an old rag doll.

[its the oxman] 23/2/2021 16:30

Nasty , back to 430p

[fionascott1234] 22/2/2021 15:55

Choppy indeed at 6% stinging drop.

[lauders] 22/2/2021 02:02

Perhaps a bit choppy here this week (?) as HCM are on this list that can be followed from the link in the following useful article:

NofS - If you have confidence in CH and the BOD (given the "hundred 1,000 invested that would seem to be the case) and HCM's products then the coin will drop one day. It may be frustrating but the products and eventual income will dictate the future. I don't have nearly as much as you at stake which is why I can perhaps be more relaxed about it. The "opportunity cost" factor is a real one.

[nerdofsteel] 21/2/2021 09:06

with a few hundred 1,000 invested here and as a long term investor (over 10 years) I am getting a bit frustrated that despite all the progress inc. our first 2 drugs launched in China and our first NDA in the United States for a wholly owned asset our mcap is effectively the same as it was 3 and a half years ago.

I look at Beigene which I contemplated investing in 3 years ago and see their massive uplift in valuation, thanks mainly to large partnership deals and then I ask myself this question:-

Given Chi-Med's huge distribution infrastructure in China, together with its knowledge of the Chinese regulatory pathways, why isn't the company leveraging that to partner with big pharma like Beigene has?

I'll sell when the mcap reaches $20 billion.

[its the oxman] 14/2/2021 15:01

Doesn't want to break above 520p.

[steeplejack] 13/2/2021 21:43

Umm...retreated sharply in the US from hitting new highs.Groundhog day.The company is clearly ‘relaxed’; about its stockmarket perception.Mr Hogg talks the talk but does he walk the walk when it comes to promoting wider investor recognition of the company’s potential.Its not as if I’ve lost money here,on the contrary,but it’s lower quartile in my portfolio and I'm searching for explanations!

[its the oxman] 05/2/2021 13:20

Near the top of our long term sideways trend, break up to 550p (hopefully sets up further gains beyond) would be really positive.

[nerdofsteel] 03/2/2021 07:26

There's certainly a history of the ADR price rising significantly the day prior to news! Only notice of results date today but the Company has been quiet for a while now. I continue to buy!

[lauders] 03/2/2021 01:02

A nice bounce towards the end of the day! Do we have a leaky ship here and news is due shortly? There I was thinking about making a top-up too. Just shows action is better than dwelling too long on one's thoughts!

[nerdofsteel] 21/1/2021 07:06

I have a small holding in Tils.

I've been unhappy for same time that Chi-Med has not a) moved to a Main Market Listing or b) completed its HK or Star Market listing

On the latter point Iam mystified on the delay. They had a prospectus 2 years ago and pulled the listing due to the HK riots, meanwhile plenty of other Biotechs went ahead and have been very very successful in building shareholder value eg, Beigene & Wuxi

Why is this Company always stuck in the slow lane when it comes to listings and also why do we not stroke more deals like Beigene have? Investing here is becoming extremely frustrating.

[steeplejack] 20/1/2021 15:01

By the by,Tiziana’s imminent move to the main market has contributed to a substantial price rise both in the U.K. and on the Nasdaq,a rise of some 20% on the latter exchange.....and it has been higher.

[steeplejack] 20/1/2021 10:51

Market cap of Tiziana is around £300m.Yet,it considers that a main board LSE listing worthwhile,despite what some others might think :)AIM Delisting and Admission to the Standard Listing Segment of Main MarketNew York/London, 20 January 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today provided a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM and admission to listing of its ordinary shares (the "Ordinary Shares") on the standard listing segment of the Official List of the Financial Conduct Authority ("FCA") (the "Official List") and admission to trading on the main market for listed securities (the "Main Market") of London Stock Exchange plc (the "London Stock Exchange") (together, "Admission").

[nerdofsteel] 19/1/2021 09:26

I agree, I think an Asian listing is what is needed here and I am mystified as to why they've not got on with it. They have a prospectus already, albeit an out of date one. I'm still completely mystified as to why they pulled the original one, and the Company has never given a proper explanation for it.

Bluebird is an interesting, although quite small investment for me.

I invested because:-

a) it is involved in rare gene therapies so will get high price points + help patients with rare diseases
b)it is forecast to grow significantly in the next 5 years and start generating cash
c) it will probably be a takeover target by big pharma

[dbadvn] 18/1/2021 12:07

No question that HCM strategy has held it back , but I think it is mostly due to the initial structure and the Chinese centricity. An Asian listing will sort that out , so my decision point is the Asian listing.

[its the oxman] 18/1/2021 11:59

Otherwise value wise may stick with hcm but a bit of diversification is generally not a bad thing.

[its the oxman] 18/1/2021 11:58

Hi NOS , off topic but I'm sure it won't offend many thx, can I ask, you convinced re Bluebird as I almost bought the other day and price is well off past highs.

[nerdofsteel] 18/1/2021 10:51

I'm invested in Bluebird

Looking, as I have been for quite a while at these:-

Exelixis
Miratis
Genmab

The last one is very intriguing, growth has been outstanding with much more to come

Given that these Co's are valued more on future growth than existing performance Chi-Med seems way undervalued to me, especially as we have 2 major events this year - Savo approval in China and Surufatinib in the U.S, the latter opening up at least $500m pa. in sales

[its the oxman] 18/1/2021 09:14

NOS, looking at hcm and beigene today presumably the latter has much more growth factored into the price now. Any other strong bio contenders your willing to share. Have been looking at bluebird bio myself as something left behind but not convinced market wants to run with it. Perhaps basket exposure via biotech growth funds is best but I like to have a bet or two on well fancied stocks as well.

[nerdofsteel] 18/1/2021 07:03

I know the Company extremely well and have met the BoD many many times so it's not just "a share" to me

On Jan 14, just two weeks after NMPA approval, the first commercial batches of surufatinib capsules (Sulanda® in China) were dispatched from our manufacturing facility in Suzhou, China, to pharmacies across the country.

[whatja] 16/1/2021 13:49

That is a lot of emotional capital tied up in HCM.

I find it hard to believe you will have to make the choice..

Boosts coming with sulanda Approval inChina and US this year....plus Savo approval...

Plus GA second tranche.